Recent genome-wide association studies (GWAS) have identified increased NAFLD susceptibility in variants of TM6SF2 (rs58542926; transmembrane 6 superfamily member 2), GCKR (rs780094, Glucokinase regulator), NCAN (rs2228603, Neurocan), and LYPLAL1 (rs12137855, Lysophospholipase-like 1) [24,25]. This evidence concerns the gene LYPLAL1 and metabolic dysfunction-associated steatotic liver disease.